⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 15, 2025

Figure S7 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer

Tianyu Qu Lei Song Jiali Xu Xiyi Lu Dandan Yin Jiali Dai Chen Zhang Renhua Guo Erbao Zhang

View Full Paper

Ask AI

Bookmark

Share

Key Points

EGFR inhibitor resistance is promoted by MYLK-AS1 through enhanced glutamine metabolism, affecting treatment outcomes.
Key evidence shows that MYLK-AS1 interacts with ILF3, impacting TKI resistance in specific lung cancer cell lines.
Analysis reveals that MYLK-AS1's role in regulating glutamine metabolism is linked to ILF3 interaction, implicating metabolic pathways.
Findings highlight the significance of understanding MYLK-AS1's function in resistance mechanisms for improved therapeutic strategies.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Observational analysis shows MYLK-AS1 enhances glutamine metabolism in non-small cell lung cancer, indicating TKI resistance mechanisms.

Abstract

MYLK-AS1 interacts with ILF3 to regulate TKI resistance in HCC827/GR and PC9/OR.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Qu et al. (2025) studied this question.

synapsesocial.com/papers/68af5bafad7bf08b1eadf349 https://doi.org/10.1158/0008-5472.29919039

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S10 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer2025
2Figure S5 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer2025
3Figure S8 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer2025
4Figure S4 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer2025
5Figure S9 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer2025